OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
6
Results
Show all
Save search
Copy query
Show results for
Unknown
(5)
Metabolomics
(1)
Repository
GNPS
(1)
Instrument Platform
LTQ FT
(1)
MaXis
(1)
Publication Date
2015
(1)
Release Date
2017
(2)
2023
(1)
2020
(1)
2012
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
Not available
S-EPMC8227801
|
biostudies-literature
Cite
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study.
Not available
S-EPMC5704992
|
biostudies-literature
Cite
Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study.
Not available
S-EPMC10040434
|
biostudies-literature
Cite
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Not available
S-EPMC5705948
|
biostudies-literature
Cite
GNPS - GNPS Paper Novel Stenothricin Analog Supporting Information.
Mass spectrometry data, NMR, and sequencing data in support of the discovery of stenothricin-GNPS. Secondary metabolite production of Streptomyces Roseosporus was compared against Streptomyces DSM5940.
ORGANISM(S):
Streptomyces (ncbitaxon:1883)
2015-07-30
|
MSV000079204
|
GNPS
Cite
Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2.
Not available
S-EPMC3387216
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets